Intervention not reported
Adverse events (AEs) · individuals with stable bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
149 questions · 149 findings · 58 reviews
No studies found 31 · 20.8%GRADE not reported 17 · 11.4%Very low 28 · 18.8%Low 41 · 27.5%Moderate 23 · 15.4%High 9 · 6%
Summary of findings table ‐ Convalescent plasma vs standard plasma
Serious adverse events · individuals with moderate to severe disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes serious adverse events compared with standard plasma (very low certainty).
1 finding from 1 review
- Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 0.8 [0.55, 1.15]3 studies · 327 participantsVery low
Bamlanivimab/etesevimab vs placebo
Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyRR 1.4 [0.45, 4.37]1 study · 1035 participantsLow
Casirivimab/imdevimab vs placebo
Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Sotrovimab vs placebo
Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab may leads to lower serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyRR 0.27 [0.12, 0.63]1 study · 868 participantsLow
Bamlanivimab vs placebo
Serious adverse events · non‐hospitalised individuals with COVID‐19
Bamlanivimab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyRR 0.51 [0.02, 12.47]1 study · 257 participantsLow
Vitamin D vs placebo or usual care
Serious adverse events · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
- Vitamin D supplementation for the treatment of COVID‐19: a living systematic review 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Mepolizumab 300 mg vs placebo
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyOdds ratio 0.84 [0.56, 1.27]1 study · 451 participantsModerate
Mepolizumab 750 mg vs placebo
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 750 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyOdds ratio 3 [0.22, 40.93]1 study · 18 participantsLow
Benralizumab 10 mg vs placebo
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 10 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyOdds ratio 0.9 [0.69, 1.17]1 study · 1129 participantsModerate
Benralizumab 30 mg vs placebo
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 30 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyOdds ratio 0.98 [0.81, 1.17]2 studies · 2235 participantsModerate
Benralizumab 100 mg vs placebo
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyOdds ratio 0.9 [0.75, 1.08]3 studies · 2333 participantsModerate
Mepolizumab 100 mg vs placebo
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyOdds ratio 0.82 [0.65, 1.05]2 studies · 1285 participantsModerate
Summary of findings: Injection therapies vs placebo or no injection control
Adverse events At final · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes adverse events At final compared with placebo or no injection control (very low certainty).
1 finding from 1 review
- RR 0.97 [0.5, 1.89]13 studies · 449 participantsVery low
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
- Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 1080 participantsVery low
Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care
Serious adverse events ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
- Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 678 participantsVery low
Casirivimab/imdevimab vs placebo
Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Bamlanivimab/etesevimab vs placebo
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyRR 1.15 [0.83, 1.59]1 study · 1035 participantsLow
Casirivimab/imdevimab vs placebo
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Sotrovimab vs placebo
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyRR 0.87 [0.66, 1.16]1 study · 868 participantsLow